University of Malaya

um.edu.my

Total trials

263

Active

40

Phase 3

9

Total enrollment

33,341

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 18 of 18 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Palonosetron2
Granisetron1
Ropivacaine + saline solution1
Ropivacaine + Dexmedetomidine1
Parestat1
Dynastat1
Pembrolizumab2
Cisplatin1
Carboplatin1
Gemcitabine1
Gengigel1
Normal saline6
Morphine2
Dexmedetomidine1
Dexametasone1
Water for1
Ketamine-Morphine PCA1
Opioid Analgesic1

Next readouts

  • 2025-08-12
  • 2025-12
  • 2025-12-01
  • 2026-07-31
  • 2026-08-30
  • 2026-08-31
  • 2026-12
  • 2027-07-01
  • 2027-07-22
  • 2027-12

Top conditions

  • Critical Illness6
  • Periodontitis6
  • Depression5
  • Postoperative Pain5
  • Orthodontic Appliance Complication5
  • Dental Anxiety4
  • Stroke4
  • Quality of Life4

Frequently asked questions about University of Malaya

How many clinical trials does University of Malaya have on ClinicalTrials.gov?
University of Malaya is listed as the lead sponsor on 263 clinical trials in ClinicalTrials.gov, 40 of which are currently active (recruiting, enrolling, or ongoing).
How many of University of Malaya's trials are in Phase 3?
9 of University of Malaya's trials are in Phase 3, spread across 18 active drug programs.
What therapeutic areas does University of Malaya focus on?
University of Malaya's most-studied conditions on ClinicalTrials.gov are Critical Illness, Periodontitis, Depression, Postoperative Pain, Orthodontic Appliance Complication.
When are University of Malaya's next clinical trial readouts?
University of Malaya has 10 upcoming primary-completion readouts tracked here; the soonest is “Pilot Study of Throat Packs Soaked in Gengigel Spray in Patients Undergoing Elective Surgery”, expected around 2025-08-12.